Immunotherapeutic strategies have transformed the treatment of a variety of diseases including cancer, autoimmune diseases, and a range of pulmonary conditions; however, much work remains to bring the full promise of these strategies to benefit more patients. Novel combination therapies along with emerging immunomodulatory strategies stand poised to take treatment paradigms of these diseases to the next level. We will discuss Biomodels preclinical models, capabilities and expertise in immunoncology, autoimmune diseases (inflammatory bowel disease, multiple sclerosis, and arthritis), graft-versus-host-disease, and pulmonary diseases (asthma and acute respiratory distress syndrome) for the development of next-generation therapies including antibodies, combinations, anti-cancer vaccines (nucleic acid or peptide-based), cell-based therapies (e.g. CAR-T, etc.), microbe or virus-derived therapies, and many others. Biomodels’ custom syngeneic models, immune-humanized mouse models, and microbiome-focused models are leveraged rationally to capture expected mechanisms of action and offer high resolution readouts. Additionally, Biomodels downstream expertise and capabilities can provide a wealth of mechanistic insights through a variety of ex-vivo immunoassays that include multi-color flow cytometry, immunophenotyping, multiplex cytokine analyses, T cell specificity assays, tumor-specific antibody detection, and many more.

свернуть